Diabetes and Glucose Management in People on Hemodialysis
Diabetes is a major cause of end-stage kidney disease (ESKD). Glycemic management is challenging in this population, and A1C, commonly used for monitoring glycemic control, is unreliable. Continuous glucose monitoring indices can be used for glycemic monitoring in people with ESKD. Dipeptidyl peptidase 4 inhibitors, incretin mimetic agents (glucagon-like peptide 1 and glucose-dependent insulinotropic peptide receptor agonists), and insulin using an automated insulin delivery system are preferred to manage diabetes in people with ESKD on hemodialysis.
Authors
- Rodolfo Javier Galindo (ORCID: https://orcid.org/0000-0002-9295-3225)
- Sreekant Avula (ORCID: https://orcid.org/0000-0003-3909-2531)
- Giuliana Arevalo
- Julia Katharina Mader (ORCID: https://orcid.org/0000-0001-7854-4233)
- Efren Chavez (ORCID: https://orcid.org/0000-0003-0814-1150)
- Shubham Agarwal (ORCID: https://orcid.org/0000-0002-7981-9603)
- Lance Sloan (ORCID: https://orcid.org/0000-0002-0370-4914)
Institutions
- University of Minnesota (US)
- University of Miami (US)
- Sam Houston State University (US)
- Medical University of Graz (AT)
- University of Alabama at Birmingham (US)
- The University of Texas Medical Branch at Galveston (US)
- University of Nebraska Medical Center (US)
Publication Details
- Journal
- Diabetes Spectrum
- Published
- 2025-02-01
- DOI
- https://doi.org/10.2337/dsi24-0015
- Citations
- 3
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 3.88